trending Market Intelligence /marketintelligence/en/news-insights/trending/bv7jr-rn0a8nyofuntn2ta2 content esgSubNav
In This List

Motif Bio delays US regulatory filing of antibiotic

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Motif Bio delays US regulatory filing of antibiotic

Motif Bio PLC said that it would be delaying the submission of a new drug application with the U.S. Food and Drug Administration for the approval of its antibiotic iclaprim.

The New-York-based biopharmaceutical company now plans to submit an application for iclaprim to treat acute bacterial skin and skin structure infections during the second quarter of 2018.

Motif Bio, which had planned to submit the application this quarter, said it was taking additional time to strengthen its filing.